Evidence map›Paper›PMID 35232464›Full record

ArticleFluids and barriers of the CNS2022

Brain barriers virtual: an interim solution or future opportunity?

Brianna M Holder, Shaina E Tolan, Kaleb K Heinrich, Kaitlin C Miller, Natalie Hudson, Geetika Nehra, Michelle E Pizzo, Steffen E Storck, William F Elmquist, Britta Engelhardt and 5 more

Open access · goldAbstract read
In one paragraph

Article in Fluids and barriers of the CNS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 5 countries.

Brianna M HolderDepartment of Biological Sciences, Science and Engineering Complex, The University of Alabama, 300 Hackberry Ln, Tuscaloosa, AL, 35487, United States.
Shaina E TolanDepartment of Biological Sciences, Science and Engineering Complex, The University of Alabama, 300 Hackberry Ln, Tuscaloosa, AL, 35487, United States.
Kaleb K HeinrichDepartment of Biological Sciences, Science and Engineering Complex, The University of Alabama, 300 Hackberry Ln, Tuscaloosa, AL, 35487, United States.
Kaitlin C MillerDepartment of Journalism and Creative Media, The University of Alabama, Tuscaloosa, AL, United States.
Natalie HudsonNeurovascular Genetics Unit, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.
Geetika NehraDepartment of Biology, The University of Kentucky, Lexington, KY, USA.
Michelle E PizzoDenali Therapeutics Inc., CA, South San Francisco, United States.
Steffen E StorckWashington University of St. Louis, St. Louis, MO, USA.
William F ElmquistDepartment of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States.
Britta EngelhardtTheodor Kocher Institute, University of Bern, Bern, Switzerland.
Irena LoryanTranslational PK/PD Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Michal ToborekDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA.
Bjoern BauerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.
Anika M S HartzSanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
Brandon J KimDepartment of Biological Sciences, Science and Engineering Complex, The University of Alabama, 300 Hackberry Ln, Tuscaloosa, AL, 35487, United States. bjkim4@ua.edu.
University of Alabama · USUniversity of Kentucky · USDenali Therapeutics (United States) · USTrinity College Dublin · IEUniversity of Alabama at Birmingham · USUniversity of Bern · CHUniversity of Miami · USUniversity of Minnesota · USUppsala University · SEWashington University in St. Louis · US

Funding

Novel Therapeutic Strategies to Resolve Neurovascular Inflammation and Repair Blood-Brain Barrier Dysfunction in EpilepsyR01NS079507 · NINDS · UNIVERSITY OF MINNESOTA · PI BAUER, BJOERN · 2012 to 2025
$4.5M
Mechanism and Therapeutic Potential of CBD to Repair Blood-Brain Barrier Dysfunction in EpilepsyR21NS131903 · NINDS · UNIVERSITY OF KENTUCKY · PI BAUER, BJOERN · 2023 to 2024
$421k
NINDS NIH HHS R01 NS079507NINDS NIH HHS R21 NS131903University of Alabama ASSUREUniversity of Alabama CARSCAUniversity of Alabama Collegiate Scholarship
6 · The paper itself

Abstract

backgroundScientific conferences are vital communication events for scientists in academia, industry, and government agencies. In the brain barriers research field, several international conferences exist that allow researchers to present data, share knowledge, and discuss novel ideas and concepts. These meetings are critical platforms for researchers to connect and exchange breakthrough findings on a regular basis. Due to the worldwide COVID-19 pandemic, all in-person meetings were canceled in 2020. In response, we launched the Brain Barriers Virtual 2020 (BBV2020) seminar series, the first stand-in virtual event for the brain barriers field, to offer scientists a virtual platform to present their work. Here we report the aggregate attendance information on two in-person meetings compared with BBV2020 and comment on the utility of the virtual platform.

methodsThe BBV2020 seminar series was hosted on a Zoom webinar platform and was free of cost for participants. Using registration- and Zoom-based data from the BBV2020 virtual seminar series and survey data collected from BBV2020 participants, we analyzed attendance trends, global reach, participation based on career stage, and engagement of BBV2020. We compared these data with those from two previous in-person conferences, a BBB meeting held in 2018 and CVB 2019.

resultsWe found that BBV2020 seminar participation steadily decreased over the course of the series. In contrast, live participation was consistently above 100 attendees and recording views were above 200 views per seminar. We also found that participants valued BBV2020 as a supplement during the COVID-19 pandemic in 2020. Based on one post-BBV2020 survey, the majority of participants indicated that they would prefer in-person meetings but would welcome a virtual component to future in-person meetings. Compared to in-person meetings, BBV2020 enabled participation from a broad range of career stages and was attended by scientists in academic, industry, and government agencies from a wide range of countries worldwide.

conclusionsOur findings suggest that a virtual event such as the BBV2020 seminar series provides easy access to science for researchers across all career stages around the globe. However, we recognize that limitations exist. Regardless, such a virtual event could be a valuable tool for the brain barriers community to reach and engage scientists worldwide to further grow the brain barriers research field in the future.

Indexed as

Central Nervous SystemCongresses as TopicCOVID-19VideoconferencingHumansSARS-CoV-2Surveys and QuestionnairesBBV2020Blood–brain barrierBrain barriers virtualCOVID-19EducationVirtual seminar series

Identifiers

PMID35232464
PMCPMC8886561
OpenAlexW4214669793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.